<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199745</url>
  </required_header>
  <id_info>
    <org_study_id>Muskelbiopsistudie Lipid05-06</org_study_id>
    <secondary_id>S-05229 (REK - Sør)</secondary_id>
    <secondary_id>13041 (NSD)</secondary_id>
    <nct_id>NCT00199745</nct_id>
  </id_info>
  <brief_title>Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity</brief_title>
  <official_title>Investigations on Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo School of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate whether differences in atorvastatin
      metabolite ratios might have a positive or negative predictive value in diagnosing
      atorvastatin muscle toxicity. A muscle biopsy is also collected and investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to investigate whether differences in atorvastatin
      metabolites ratios might have a positive or negative predictive value in diagnosing
      atorvastatin muscle toxicity. A muscle biopsy is also collected and investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare ratios atorvastatin metabolites to atorvastatin in patients with confirmed atorvastatin-induced myopathy compared to healthy volunteers</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phenotypic differences in isolated muscle cells of patients experiencing muscle toxicity compared to a control group</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Muscular Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected atorvastatin induced muscle adverse events

          -  Signed informed consent

          -  18 years of age or older

          -  Able to donate blood samples

          -  Ongoing treatment with atorvastatin (not necessary if patients only donate a muscle
             biopsy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjetil Retterstøl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lipidklinikken, Rikshospitalet-Radiumhospitalet HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Åsberg, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lipidklinikken, Rikshospitalet-Radiumhospitalet HF</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 9, 2012</last_update_submitted>
  <last_update_submitted_qc>May 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <keyword>statin</keyword>
  <keyword>statins</keyword>
  <keyword>statin therapy</keyword>
  <keyword>adverse events</keyword>
  <keyword>side effect</keyword>
  <keyword>Myotoxicity</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>Atorvastatin Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

